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INTRODUCTION
The idea that analgesic treatment initiated before the injury
would be more effective than the same analgesic treatment
given after the injury was named protective analgesia and
showed various efficacies in many reports (1, 2). Transmis-
sion of pain signals evoked by tissue damage leads to sensi-
tization of the peripheral and central pain pathways. Theo-
retically, protective analgesia using opioids or antihyperal-
gesic drugs such as N-methyl-D-aspartic acid (NMDA) -
receptor antagonists and gabapentin, may interfere with the
induction and maintenance of the sensitization. Therefore,
immediate postoperative pain may be reduced, and the devel-
opment of chronic pain may be prevented (1). Gabapentin
(1-[aminomethyl]-cyclohexane acetic acid) has been shown
to provide effective analgesia for various neuropathic pains.
However, the use of gabapentin before the establishment of
neuropathic pain has been rarely studied. 
The α 2δ 1-subunit of the voltage dependent calcium chan-
nel (the α 2δ 1-subunit) is the only known binding site for
gabapentin (3-5). The α 2δ 1-subunit is up-regulated in the
dorsal root ganglion (DRG) and precedes the onset of neu-
ropathic pain in a spinal nerve injury (6-8), and four days
consecutive treatment of intraperitoneal gabapentin reduced
the level of the α 2δ 1-subunit in the Chemotherapy-induced
neuropathy (9). 
Therefore, this study was designed to determine whether
early gabapentin treatment before neuropathic pain estab-
lishment has a protective analgesic effect on neuropathic pain
and compared its effect to the late treatment, and as the poten-
tial mechanism of protective action, the α 2δ 1-subunit was
evaluated.
MATERIALS AND METHODS
These experiments were approved by the Institutional
Animal Care and Committee of our Biomedical Research
Institute, and were performed in accordance with the guide-
lines of the Committee for Research and Ethical Issues of
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Protective Effects of Gabapentin on Allodynia and α α 2δ 1-Subunit of
Voltage-dependent Calcium Channel in Spinal Nerve-Ligated Rats
This study was designed to determine whether early gabapentin treatment has a
protective analgesic effect on neuropathic pain and compared its effect to the late
treatment in a rat neuropathic model, and as the potential mechanism of protective
action, the α 2δ 1-subunit of the voltage-dependent calcium channel (α 2δ 1-subunit) was
evaluated in both sides of the L5 dorsal root ganglia (DRG). Neuropathic pain was
induced in male Sprague-Dawley rats by a surgical ligation of left L5 nerve. For the
early treatment group, rats were injected with gabapentin (100 mg/kg) intraperitoneal-
ly 15 min prior to surgery and then every 24 hr during postoperative day (POD) 1-4.
For the late treatment group, the same dose of gabapentin was injected every 24
hr during POD 8-12. For the control group, L5 nerve was ligated but no gabapentin
was administered. In the early treatment group, the development of allodynia was
delayed up to POD 10, whereas allodynia was developed on POD 2 in the control
and the late treatment group (p<0.05). The α 2δ 1-subunit was up-regulated in all
groups, however, there was no difference in the level of the α 2δ 1-subunit among
the three groups. These results suggest that early treatment with gabapentin offers
some protection against neuropathic pain but it is unlikely that this action is medi-
ated through modulation of the α 2δ 1-subunit in DRG.
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IASP (10). 
Animal preparation
Male Sprague-Dawley rats, weighing 130-180 g, were
housed in separate cages with a 12/12 hr day/night cycle and
food and water provided ad libitum. The rats were allowed
to acclimatize for 5-7 days before the experiments. 
Model of neuropathic pain 
Neuropathic pain was induced using the procedure des-
cribed by Kim and Chung (11, 12). Briefly, the rats were
anesthetized with 2.5% enflurane in O2 through a mask. A
dorsal midline incision was made from L3 to S2. Under micro-
scopic guidance, the left L6 transverse process was partly
resected to visualize the L4 and L5 spinal nerves. The left
L5 spinal nerve immediately distal to the DRG was isolated
and ligated tightly with a 6-0 black silk.
Gabapentin administration
Intraperitoneal gabapentin (Park-Davis, Ann Arbor, MI,
U.S.A.) 30-300 mg/kg was reported to be an effective anal-
gesic dose (7, 12-15). Gabapentin was dissolved in sterile
saline 1 mL and injected intraperitoneally. One hundered
mg/kg of Gabapentin was injected intraperitoneally 15 min
before the nerve ligation (postoperative day [POD] 0) and
then at 24 hr intervals during POD 1-4 in the early treat-
ment group (n=21). For the late treatment group, the same
dose of gabapentin was administered every 24 hr during POD
8-12 (n=21). The control group underwent the same nerve
ligation but did not receive gabapentin (n=21). 
Test for tactile allodynia 
An observer who was blinded to the study design per-
formed the tactile allodynia tests. Baseline values were ob-
tained before nerve ligation. Test for tactile allodynia in all
groups was carried at 8 a.m. everyday before next gabapentin
administration to avoid diurnal variation. 
For the baseline and POD tests, each rat was placed in a
clear plastic cage (24×13×13 cm) with a 4×4-mm wire-
mesh grid floor and allowed to acclimatize for at least 15 min.
A series of von Frey hairs (number: 4.17, 4.31, 4.56, 4.74,
4.93, 5.07, and 5.18; Stoelting, Wood Dale, IL, U.S.A.) start-
ing with 4.31 were applied in consecutive sequence through
to the grid floor to the ventral surface of the operated hind-
paw of each rat with a pressure causing the filament to buckle. 
Brisk paw lifting within 5 sec indicated a positive response
and prompted the use of the next weaker filament. An absence
of a paw withdrawal response after 5 trials prompted the use of
the next stronger filament. This paradigm was continued
until five more measurements had been made after recording
the initial change in the behavioral response. 
50% gm threshold=10(Xf+κ δ )/10,000
Where Xf=the value of the final von Frey filament used
(in log units), κ =the tabular value for the pattern of positive/
negative responses (from Chaplan et al. [17]), and δ =the
mean difference between stimuli (in log units). 
Rats showing any sign of motor dysfunction, including ab-
normal ambulation or placing/stepping reflex were excluded. 
Harvesting the DRG
The DRGs were collected at POD 7, 14, and 21 in each
group. Six rats in each group were euthanized in a CO2 gas
chamber at POD 7, 14, and 21 after the surgery. The previ-
ous incision was reopened and widened. The L5 nerve was
identified with a black silk tie and dissected carefully to the
point of the DRG. The DRG was resected and preserved in
a -70℃ refrigerator for Western blotting. The contralateral
L5 DRG was also obtained for comparison. The level of the
α 2δ 1-subunit in the DRG of nerve-ligated side was compared
with the contralateral DRG and was expressed as the % of
the contralateral side.
Western blot
The isolated DRG was homogenized with a glass Teflon
homogenizer in an ice-cold homogenization buffer (10 mM
Tris, pH 7.4, 1% Nonidet P-40, 150 mM NaCl, 0.1% SDS,
andprotease inhibitors) and centrifuged at 20,000 g for 15
min. The supernatants were electrophoresed in 8% SDS-poly-
acrylamide gel and transferred to PVDF membranes (Milli-
pore, Billerica, MA, U.S.A.). The membranes were incubat-
ed with a polyclonal antibody recognizing the α 2δ 1-subunit
(cat#: AB5604-200 μ L, Chemicon International, Temecula,
CA, U.S.A.) or a monoclonal antibody recognizing the neu-
ron specific beta III Tubulin (Abcam, Cambridge, U.K.) for
16 hr. After washing with Tris-buffered saline/Tween (0.05
%), the blots were incubated with horseradish peroxidase-
conjugated anti-rabbit, or anti-mouse IgGs, and developed
using a LAS-3000 chemiluminescence imaging system (Fuji
Film, Tokyo, Japan).
Data analysis
Kruskal-Wallis ANOVA on ranks and the subsequent post
hoc comparisons (Dunn’s multiple comparisons) were per-
formed for allodynia and the level (%) of α 2δ 1-subunit between
the three groups. A Friedman repeated measures ANOVA
on Ranks (Tukey test for multiple comparison) was used to
compare the time-dependent changes in allodynia. Chi-square
test was used for % comparison of non allodynic rats between
the groups. A p<0.05 was considered significant. 148 T.S. Hahm, H.J. Ahn, C.-D. Bae, et al.
RESULTS
Allodynia 
In the early treatment group, PWT did not decrease up
to POD 10, whereas, in the control and the late treatment
groups, PWT significantly decreased from the baseline value
on POD 2 (p<0.05 compared to baseline value). PWT was
higher in the early treatment group than in the control and
the late treatment groups until POD 14 (p<0.05). The late
treatment with gabapentin failed to show any significant
anti-allodynic effect (Fig. 1).
The 83.3% of rats in the early treatment group did not
develop allodynia on POD 7, which was significantly high-
er than in the control (3.3%) and the late treatment group
(12.5%) (p<0.05). On POD 14, the 36.4% of rats in the early
treatment group did not develop allodynia, which was still
higher than in the control (0%) and the late treatment groups
(8.3%) (p<0.05). On POD 21, 16.7% in the early treatment
group did not develop allodynia, whereas all the rats devel-
oped allodynia in the control and the late treatment group
Fig. 2. Percentage of non-allodynic rats at each week. There was
a higher number of rats that did not develop allodynia at the end
of each 1, 2, and 3 weeks in the early treatment group than in the
control or the late treatment group. 
*, p<0.05 compared to the control group; 
� , p<0.05 compared to
the late treatment group.
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Fig. 3. Level of the α 2δ 1-subunit. Data are the mean±SD. Level of the α 2δ 1-subunit was similar in the control, late, and early treatment groups
at 1, 2, and 3 weeks after surgery. (A) The α 2δ 1-subunit level. The α 2δ 1-subunit level was expressed the % contralateral side (N=6 in each
group). (B) Western images from the immunoblot images of individual rats in the early and the late treatment group. 
C, contralateral dorsal root ganglion; L, ligated dorsal root ganglion.
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Fig. 1. Development of allodynia in each group.
Data are the mean±SD. Decrease of PWT
occurred in POD 10 in the early treatment group
and POD 2 in the control and the late treatment
group (p<0.05, symbols indicating significant
difference were omitted for the sake of clarity).
Black and white bars on the X-axis represent
the duration of gabapentin administration in
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PWT, paw withdrawal threshold; POD, post-
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(p<0.05) (Fig. 2).
Expression of α 2δ 1-subunit
The α 2δ 1-subunit in the ligated side DRG was up-regu-
lated in all groups (p<0.05). 
However, the level of the α 2δ 1-subunit between the three
groups at 1, 2, and 3 weeks after nerve ligation were not dif-
ferent (Fig. 3). 
DISCUSSION
In the present study, the early gabapentin treatment pro-
duced a significant anti-allodynic effect, whereas this effect
was absent in the late gabapenitn treatment. However, ga-
bapentin treatment did not affect the level of the α 2δ 1-sub-
unit in DRG..
Protective effect for neuropathic pain by gabapentin has
been shown in a few recent studies. Gabapentin when given
before hysterectomy reduced postoperative pain (18). Kaneko
et al. (19) showed that pre-treatment of gabapentin was three
times more potent in pain relief than post-treatment in for-
malin hindpaw injection. This was a postoperative pain or
formalin injection study with single intrathecal gabapentin
administration. For neuropathic pain, Coderre et al. (20) re-
ported that the early consecutive treatment with gabapentin,
but not the late treatment, showed anti-allodynic effect in a
chronic constriction injury of sciatic nerve. In their study, rats
were injected with gabapentin (30, 100 or 300 mg kg-1)
intraperitoneally 15 min prior to the surgery and then dur-
ing POD 1-4 (pre-treatment group), or during POD 8-12
(post-treatment group) at 12 hr intervals. They showed that
the early treatment has an anti-allodynic effect compared to
the vehicle injection, whereas this effect was not evident in
the late treatment group. 
In our study, the anti-allodynic effect of gabapentin in the
early treatment group persisted even after discontinuing the
drug. In contrast, the late treatment with gabapentin did not
have any apparent efficacy against allodynia. Peak analgesic
effect of gabapentin appears at 1-2 hr after intraperitoneal
injection and decreases to pre-injection level within 4-5 hr
(9, 12, 15, 21). Therefore, the persistent anti-allodynic effect
in the early treatment group, even after discontinuing the
drug, might imply some type of structural change in the ner-
vous system.
In our study, the level of the α 2δ 1-subunit in DRG was not
different among the groups. There was only one study that
dealt the effect of gabapentin treatment on the level of the
α 2δ 1-subunit (9). They administered gabapentin during the
peak neuropathic pain period in a chemotherapy induced
neuropathy model and compared 1 day-gabapentin treatment
with 4 days-treatment (n=7, each group) revealing that only
repeated dosing was effective in reducing allodynia and the
α 2δ 1-subunit in dorsal spinal cord. Interestingly, in their study,
no up-regulation of the α 2δ 1-subunit or reduction by gaba-
pentin treatment, was shown in the DRG. Our study dealt
with nerve ligation induced neuropathy and measured the
α 2δ 1-subunit in the DRG. In the case of nerve ligation, up-
regulation of the α 2δ 1-subunit was much higher in the DRG
than in the dorsal spinal cord (6, 8). In addition, we com-
pared the early and late treatment with gabapentin, not the
duration of treatment. These differences of the study design
might have resulted in different outcomes, however, the α 2δ 1-
subunit in the dorsal horn need to be evaluated in a further
study. 
Excitatory amino acids such as NMDA (20, 22) and their
receptors (23), gamma-aminobutyric acid receptors (24, 25),
norepinephrine (26, 27), and K+ channels (27, 28) have been
suggested to involve in analgesic mechanisms of gabapentin.
However, these mechanisms have not been verified for the
protective effect of gabapentin yet. Among them, protective
effect of NMDA antagonist is well known (29, 30), and
NMDA receptor antagonist attenuated the up-regulation of
the NMDA receptor subunit when administered before a
nerve injury (29). The α 2δ 1-subunit enhances the Ca2+ chan-
nel currents (31, 32), and longer depolarization and concomi-
tant calcium entry facilitate the release of glutamate and sub-
stance P from the nerve ending. This activates the NMDA
receptors and results in a wind-up phenomenon (33). Gaba-
pentin by blocking the α 2δ 1-subunit might prevent the whole
cascade of subsequent events. Future studies are needed to
examine the mechanisms of the protective role of gabapentin.
In the early treatment group, allodynia finally developed
after 2 weeks. The only way of preventing the sensitization
of the nociceptive system might be to block all pain signals
originating from the surgical wound completely from the
time of the incision until the final wound healing (1). Xie
et al. (34) also reported that a shorter duration of the block-
ade of nociceptive input is one of the reasons for the pre-treat-
ment failure. Therefore, further study is needed to find that
a longer treatment of gabapentin that can cover the whole
period of the noxious peripheral input could prevent the devel-
opment of allodynia. 
We started gabapentin before nerve injury for protective
analgesia, however, it is hardly the case in clinical situation
except very high probability of development of neuropathic
pain such as limb amputation. Therefore, gabapentin treat-
ment shortly after nerve injury and before neuropathic pain
development might give valuable information on the tim-
ing of treatment.
In conclusion, the results of our study demonstrated a pro-
tective analgesic effect of gabapentin in a L5 ligation model.
Administration of gabapentin before the neuropathic pain
establishment showed long lasting anti-allodynic effect. How-
ever, the mechanism is not related with the suppression of
the up-regulation of the α 2δ 1-subunit in DRG. Our result
implies that early administration of gabapentin after injury150 T.S. Hahm, H.J. Ahn, C.-D. Bae, et al.
to the patients who have a high probability to develop neu-
ropathic pain would be beneficial. Humane studies and fur-
ther steps to elucidate underlying mechanisms are essential
for gabapentin-induced protective analgesia.
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